Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms BALANCE-EXTEND
- Sponsors AbbVie; AbbVie Germany
- 15 Jun 2022 Pneumococcal-13-valent-CRM197-vaccine-conjugate has been introduced in the treatment. Primary endpoints amended.
- 04 Jun 2022 Results assessing final safety and efficacy of UPA in BALANCE-EXTEND, enrolling pts who completed either BALANCE-1 or BALANCE-2 presented at the 23rd Annual Congress of the European League Against Rheumatism
- 24 May 2022 According to an Abbvie media release, the study data will be presented in European Alliance of Associations for Rheumatology (EULAR) 2022 Congress.